SHARE

Cellceutix Corp (OTCMKTS:CTIX) recently attended the ASCO meeting in Chicago, along with a poster on Kevetrin. As per the reports from the company, the poster attracted a lot of attention of specialists from both academia and the industry. The drug has completed its phase-1 clinical trials and is ready to be moved to phase-2. However, that is not the only drug by the company, which can turn out to be immensely profitable. CTIX has also been working on a competitor drug for daptomycin, Brilacidin, which is also in the phase-2 of clinical trials.

CTIX has become a growing clinical stage company with a focus on innovative therapies for dermatology, oncology and anti-biotics. The company’s poster at ASCO provided the attendees with information from the phase-1 clinical trial of Kevetrin. As per the results from the trials, Kevetrin is safe and can be administered as a single-dose treatment over repeated cycles. So far there have been no adverse effects.

The results also showed a significant increase in p21 expression, in a large number of subjects. Concluding from the results, the company believes that the drug can become an effective mono-therapy for ovarian and gynecological cancer sufferers. Cellceutix Corp (OTCMKTS:CTIX) also stated that the ASCO attendees, from all over the world, showed significant interest in the drug and its response upon p53. Kevetrin’s mechanism of action involves restoring p53 function. The drug then initiates a natural response of apoptosis and cell cycle arrest. The results also concluded that they drug can be used in conjunction with other treatments and as well as a stand-alone therapy.

Brilacidin is, however, the current drug under the spotlight. So far CTIX has seen a lot of potential in the drug and is thought to eventually replace daptomycin as the primary drug of choice. Unfortunately, investors will have to wait for the drug to come out, so they can reap its profits. Currently, the drug has only just begun enrollment of its phase-2 clinical trials and it would be a while before the drug reaches the market.

Cellceutix Corp (OTCMKTS:CTIX) registered a rise of 5.6% at the close of the June 9 session, after trading 117.72 million shares, to close at $2.83.

SHARE
Previous articleMedical Marijuana Inc (OTCMKTS:MJNA)’s RSHO Gets Shelf Stability Approval
Next articlePharmacyte Biotech Inc (OTCMKTS:PMCB) Announces Further Study into Malignant Ascites
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.

LEAVE A REPLY